Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Wave Life Sciences (WVE) EPS (Weighted Average and Diluted) (2021 - 2025)

Wave Life Sciences' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.29 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 207.41% year-over-year to -$0.29; the TTM value through Dec 2025 reached -$1.21, down 75.36%, while the annual FY2025 figure was -$1.21, 72.86% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.29 in Q4 2025 per WVE's latest filing, up from -$0.32 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.27 in Q4 2024 to a low of -$0.78 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.32, with a median of -$0.29 recorded in 2025.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 280.0% in 2024 against a maximum downside of 771.43% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.61 in 2021, then rose by 26.23% to -$0.45 in 2022, then soared by 66.67% to -$0.15 in 2023, then skyrocketed by 280.0% to $0.27 in 2024, then tumbled by 207.41% to -$0.29 in 2025.
  • Per Business Quant, the three most recent readings for WVE's EPS (Weighted Average and Diluted) are -$0.29 (Q4 2025), -$0.32 (Q3 2025), and -$0.31 (Q2 2025).